Navigation Links
Later Use of Clot-Buster After Stroke Possible: Study
Date:9/14/2008

tPA can be safely given beyond the current 3-hour limit, international researchers find

SUNDAY, Sept. 14 (HealthDay News) -- European researchers who showed that the clot-dissolving drug tPA could safely be used within three hours after a stroke now say the limit can be extended to four-and-a-half hours.

"We now have a three-hour limit mandated by authorities," said Dr. Nils Wahlgren, a neurology professor at the Karolinska Institute in Sweden and leader of an international group reporting Sunday in the online version of The Lancet. "Our data indicate that it is safe to extend that from three hours to four-and-a-half hours. The risk of hemorrhagic complications is not significantly different from the earlier time limit."

Tissue plasminogen activator (tPA), also known as the drug alteplase, is the approved treatment for the most common kind of stroke, in which a blood clot blocks a brain artery. The three-hour post-stroke time limit has been set because of fears that use of the clot-dissolving drug beyond that period might cause dangerous bleeding or other complications.

The new report is the latest from a study requested by European authorities after doubts arose about the safety of tPA in stroke treatment, which was approved in 1996 by the U.S. Food and Drug Administration. It was approved in 2002 in Europe.

The study compared the outcomes of 664 people who were given tPA between three and four-and-a-half hours after a stroke against almost 12,000 who received the drug within three hours of an attack.

The study found a death rate of 12.7 percent in the following three months for the three-hour group and 12.2 percent for those getting tPA later. In the early group, 58 percent achieved the ability of independent action, compared to 56.3 percent in the later-administration group.

"We recorded no significant differences between the 3- to 4.5-hour cohort and the within 3-hour cohort for any outcome measure," the researchers reported.

The bottom line, according to Wahlgren: "if patient treatment has been delayed, it is still safe to treat a patient beyond the time limit of three hours."

The results were expected to be presented at an international meeting in Stockholm in November, "when we will recommend a change in the guidelines," Wahlgren said. "I expect it would be accepted by the international community, both in the United States and Europe, and in the rest of the world."

But the new results do not necessarily mean an end to the three-hour limit, cautioned Dr. Larry Goldstein, professor of neurology at Duke University and director of the Duke Stroke Center in Durham, N.C.

"They are consistent with a combined analysis done some time ago that suggested we might be able to treat beyond three hours," Goldstein said. "But those were observational studies, as was this one. Controlled trials done to test that belief have not shown benefit."

It will take a change in the current guidelines to alter the three-hour limit, he said, and the overall benefit of tPA is greater when it is given earlier. "The sooner you get blood to the brain, the better," Goldstein said.

More information

There's more on tPA at the American Heart Association.



SOURCES: Nils Walhgren, M.D., professor, neurology, Karolinska Institute, Stockholm, Sweden; Larry Goldstein, M.D., professor of neurology, Duke University, Durham, N.C.; Sept. 14, 2008, The Lancet online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 6 Years Later, 9/11 Health Questions Linger
2. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
3. SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System
4. Early treatment of children with bilateral amblyopia essential, according to multisite study
5. AAAAI: Early Day Care Attendance May Protect Infants From Later Developing Asthma, From the Journal of Allergy and Clinical Immunology
6. Dementia in More Educated Hits Later But Harder
7. Contamination from depleted uranium found in urine 20 years later
8. Early Weight Gain Can Mean Heart Trouble Later in Life
9. Fetal heart rate yields clues to childrens later development
10. Fetal Heart Rate Points to Later Child Development
11. Trauma earlier in life may affect response to stress years later
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Later Use of Clot-Buster After Stroke Possible: Study
(Date:12/9/2016)... Ohio (PRWEB) , ... December 09, 2016 , ... ... of miniature, folded, pharmaceutical inserts and outserts. As a means of expanding ... This addition will enable Flottman to individually code professional inserts (PIs) and patient ...
(Date:12/9/2016)... ... , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” a ... as an organ donor for the 123,000 people in the United States who are ... up to 8 saves through organ donation and enhance many others through tissue donation, ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing ... wellness program, at their world headquarters of Omni La Costa Resort & Spa in ... anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
Breaking Medicine Technology: